Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
| Revenue (Most Recent Fiscal Year) | $1.04B |
| Net Income (Most Recent Fiscal Year) | $-190.60M |
| PE Ratio (Current Year Earnings Estimate) | 9.34 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.36 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.31 |
| Pre-Tax Margin (Trailing 12 Months) | -6.45% |
| Net Margin (Trailing 12 Months) | -13.63% |
| Return on Equity (Trailing 12 Months) | -0.52% |
| Return on Assets (Trailing 12 Months) | -0.17% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.20 |
| Inventory Turnover (Trailing 12 Months) | 1.98 |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.71 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.23 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.71 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 54.28M |
| Free Float | 52.54M |
| Market Capitalization | $344.66M |
| Average Volume (Last 20 Days) | 1.30M |
| Beta (Past 60 Months) | 2.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.40% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |